☆ 4.7 Article

Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study

ANNALS OF ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz et al.

Summary: In the DESTINY-Breast03 trial, trastuzumab deruxtecan showed superior progression-free survival compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. The study aimed to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine. The results demonstrated that trastuzumab deruxtecan had the longest reported median progression-free survival and improved overall survival, reaffirming its role as the standard of care in the second-line setting.

LANCET (2023)

添加到收藏夹

Article Oncology

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

M. Di Maio et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Impact of Blinding on Patient-Reported Outcome Differences Between Treatment Arms in Cancer Randomized Controlled Trials

Fabio Efficace et al.

Summary: Concerns regarding potential bias in patient-reported outcome (PRO) results in open-label cancer randomized controlled trials (RCTs) were investigated. The study found that open-label trials did not favor experimental treatment over blinded trials, and the effect of blinding on distal vs proximal PROs did not differ significantly. Novel evidence-based data support the validity of PRO results from open-label cancer RCTs.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes et al.

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.

Erika P. Hamilton et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

A. Gennari et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe

L. Moscetti et al.

Summary: In recent years, there has been an increase in trials incorporating health-related quality of life (HRQoL) data, but the impact on regulatory decision making in Europe and clinical practice is still unclear. An analysis of HRQoL data from clinical trials of drugs for hormone receptor positive/HER2-negative advanced/metastatic breast cancer indicated new treatments had no detrimental effect on HRQoL. Efforts should be made to increase the visibility of HRQoL results to provide clinicians and patients with more QoL data.

BREAST (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Hospitalization rates for complications due to systemic therapy in the United States

Anshul Saxena et al.

Summary: This study aimed to estimate the trends and burdens associated with systemic therapy-related hospitalizations using nationally representative data. The analysis revealed an increasing trend in hospitalization rates for systemic therapy-related complications, with anemia, neutropenia, and sepsis being the most common causes. Implementing measures to manage and prevent these complications is crucial in reducing hospitalizations and alleviating the burden on the healthcare system.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Health Care Sciences & Services

Patient-reported outcomes in breast cancer FDA drug labels and review documents

Kyungwan Hong et al.

Summary: Although PROs are important to breast cancer patients, they are rarely mentioned in FDA drug labels for breast cancer drugs approved between 2000 and 2019. However, FDA medical review documents do include information on PRO measures and endpoints, with reviewers citing issues such as lack of meaningfulness, clinical significance, content validity, and inadequate analytical methods.

JOURNAL OF PATIENT-REPORTED OUTCOMES (2021)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Paolo Tarantino et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Health Care Sciences & Services

The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis

Samantha Cruz Rivera et al.

HEALTH AND QUALITY OF LIFE OUTCOMES (2019)

添加到收藏夹

Editorial Material Oncology

Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials

Jessica K. Roydhouse et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Review Health Care Sciences & Services

The importance of patient-reported outcomes in clinical trials and strategies for future optimization

Rebecca Mercieca-Bebber et al.

PATIENT-RELATED OUTCOME MEASURES (2018)

添加到收藏夹

Article Oncology

ESMO-Magnitude of Clinical Benefit Scale version 1.1

N. I. Cherny et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma

Franck Bonnetain et al.

EUROPEAN JOURNAL OF CANCER (2010)

添加到收藏夹

Review Oncology

Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials

Kim Cocks et al.

EUROPEAN JOURNAL OF CANCER (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.